12:00 AM
Jun 11, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Taltorvic ridaforolimus regulatory update

FDA issued a complete response letter for an NDA from Merck for ridaforolimus as maintenance therapy for metastatic soft tissue or bone sarcoma patients with stable disease following chemotherapy. According...

Read the full 129 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >